Maki, Robert

Publications

Sort by

Co-Author Network

selected publications

Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 106
A framework for advancing our understanding of cancer-associated fibroblasts. Nature reviews. Cancer. 2020 Review GET IT
Times cited: 2218
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future oncology (London, England). 2019 Academic Article GET IT
Times cited: 11
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Scientific reports. 2019 Academic Article GET IT
Times cited: 43
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2019 Academic Article GET IT
Times cited: 8
Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer. 2019 Academic Article GET IT
Times cited: 10
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2019 Academic Article GET IT
Times cited: 61
Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. BMC cancer. 2019 Academic Article GET IT
Times cited: 15
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 Academic Article GET IT
Times cited: 58
Novel HMGA2-YAP1 fusion gene in aggressive angiomyxoma. 2019 GET IT
Times cited: 12
Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. British journal of cancer. 2019 Academic Article GET IT
Times cited: 33
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019 Academic Article GET IT
Times cited: 20
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 184
Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review. JAMA oncology. 2019 Review GET IT
Times cited: 92
An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. Nature cell biology. 2019 Academic Article GET IT
Times cited: 41
Sorafenib for Advanced and Refractory Desmoid Tumors. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 311
Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA oncology. 2018 Academic Article GET IT
Times cited: 124
TERT promoter mutations in solitary fibrous tumour. Histopathology. 2018 Academic Article GET IT
Times cited: 47
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 35
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. The oncologist. 2018 Academic Article GET IT
Times cited: 15
A Method to Summarize Toxicity in Cancer Randomized Clinical Trials. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Review GET IT
Times cited: 13
Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Review GET IT
Times cited: 57
Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Review GET IT
Times cited: 38
Sarcoma: The Merging of Science and Clinical Care. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Review GET IT
Times cited: 3
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. The Lancet. Oncology. 2017 Academic Article GET IT
Times cited: 969
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 118
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. The oncologist. 2017 Academic Article GET IT
Times cited: 61
Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2017 Academic Article GET IT
Times cited: 248
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA oncology. 2017 Academic Article GET IT
Times cited: 94
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecologic oncology. 2017 Academic Article GET IT
Times cited: 56
Targeting sarcoma tumor-initiating cells through differentiation therapy. Stem cell research. 2017 Academic Article GET IT
Times cited: 8
Treatment of soft tissue sarcoma: a focus on earlier stages. Future oncology (London, England). 2017 Review GET IT
Times cited: 17
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 146
Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy. Gastroenterology clinics of North America. 2016 Review GET IT
Times cited: 5
Monogenic and polygenic determinants of sarcoma risk: an international genetic study. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 160
Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review. JAMA oncology. 2016 Review GET IT
Times cited: 17
Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome medicine. 2016 Academic Article GET IT
Times cited: 74
Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options. Expert review of clinical pharmacology. 2016 Academic Article GET IT
Times cited: 4
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet (London, England). 2016 Academic Article GET IT
Times cited: 585
Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches. Oncology and therapy. 2016 Review GET IT
Times cited: 11
Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation. 2015 GET IT
Times cited: 615
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 663
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. European journal of cancer. 2015 Academic Article GET IT
Times cited: 80
Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. Frontiers in oncology. 2015 Review GET IT
Times cited: 36
Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. The oncologist. 2015 Review GET IT
Times cited: 25
Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. European journal of cancer. 2015 Review GET IT
Times cited: 60
Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. 2015 GET IT
Times cited: 28
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma. 2015 Academic Article GET IT
Times cited: 50
GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Review GET IT
Times cited: 39
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European journal of cancer. 2015 Academic Article GET IT
Times cited: 29
Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. The oncologist. 2015 Academic Article GET IT
Times cited: 58
Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions. American journal of clinical oncology. 2014 Academic Article GET IT
Times cited: 28
Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. European journal of cancer. 2014 Academic Article GET IT
Times cited: 97
A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014 Academic Article GET IT
Times cited: 164
Patient-derived xenografts for individualized care in advanced sarcoma. 2014 GET IT
Times cited: 139
Cutaneous metastasis of a perivascular epithelioid cell tumor. Cutis. 2014 Letter GET IT
Times cited: 3
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 247
Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?. Sarcoma. 2014 Academic Article GET IT
Times cited: 10
Malignant peripheral nerve sheath tumors. The oncologist. 2014 Review GET IT
Times cited: 265
International expert opinion on patient-tailored management of soft tissue sarcomas. European journal of cancer. 2013 Review GET IT
Times cited: 38
Advanced chondrosarcomas: role of chemotherapy and survival. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 194
When Benign Tumors Mimic Malignancies: A Case of Lymphangiomatosis Masquerading as Metastatic Disease. Rare cancers and therapy. 2013 Academic Article GET IT
Times cited: 442
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Annals of surgery. 2013 Academic Article GET IT
Times cited: 127
Angiosarcomas and other sarcomas of endothelial origin. Hematology/oncology clinics of North America. 2013 Review GET IT
Times cited: 27
Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 39
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2013 Academic Article GET IT
Times cited: 176
Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leukemia research. 2013 Academic Article GET IT
Times cited: 22
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma. 2013 Academic Article GET IT
Times cited: 153
Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. Frontiers in oncology. 2013 Academic Article GET IT
Times cited: 12
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013 Academic Article GET IT
Times cited: 119
Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. 2013 GET IT
Times cited: 43
Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications. Targeted oncology. 2012 Academic Article GET IT
Times cited: 13
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2012 Academic Article GET IT
Times cited: 1126
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 37
The rule of fives, a simple way to stratify risk for primary gastrointestinal stromal tumors (GIST). Clinical sarcoma research. 2012 Academic Article GET IT
Times cited: 678
New strategies in sarcoma therapy: linking biology and novel agents. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Review GET IT
Times cited: 11
Randomization and statistical power: paramount in trial reproducibility (even for rare cancers). The oncologist. 2012 Comment GET IT
Times cited: 2
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 88
Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Letter GET IT
Times cited: 24
Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. Journal of the American College of Surgeons. 2012 Academic Article GET IT
Times cited: 153
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. European journal of cancer. 2012 Academic Article GET IT
Times cited: 123
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer. 2012 Academic Article GET IT
Times cited: 98
Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin. The oncologist. 2012 Letter GET IT
Times cited: 9
Ifosfamide in the neoadjuvant treatment of osteogenic sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Editorial Article GET IT
Times cited: 14
New therapeutic targets in soft tissue sarcoma. Advances in anatomic pathology. 2012 Review GET IT
Times cited: 43
Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery. Cancer investigation. 2012 Review GET IT
Times cited: 11
The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. Genes, chromosomes & cancer. 2012 Academic Article GET IT
Times cited: 90
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 84
Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Letter GET IT
Times cited: 6
First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. European journal of cancer. 2012 Academic Article GET IT
Times cited: 58
Targeted therapy in sarcoma: should we be lumpers or splitters?. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2012 Academic Article GET IT
Comments regarding lung metastasis surgery for sarcoma. Oncology (Williston Park, N.Y.). 2011 Comment GET IT
CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. Genes, chromosomes & cancer. 2011 Academic Article GET IT
Times cited: 19
High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes, chromosomes & cancer. 2011 Academic Article GET IT
Times cited: 310
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Annals of surgical oncology. 2011 Academic Article GET IT
Times cited: 46
Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2011 Academic Article GET IT
Times cited: 121
Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 79
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 274
A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 39
Eribulin in soft-tissue sarcomas. The Lancet. Oncology. 2011 Comment GET IT
Times cited: 5
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet. Oncology. 2011 Academic Article GET IT
Times cited: 821
Chemotherapy in clear cell sarcoma. Medical oncology (Northwood, London, England). 2011 Academic Article GET IT
Times cited: 52
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2011 Academic Article GET IT
Times cited: 195
Advances in sarcoma genomics and new therapeutic targets. Nature reviews. Cancer. 2011 Information Resource GET IT
Times cited: 332
A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes, chromosomes & cancer. 2011 Academic Article GET IT
Times cited: 425
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. 2011 GET IT
Times cited: 394
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Investigational new drugs. 2011 Academic Article GET IT
Times cited: 73
Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 214
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. European journal of cancer. 2011 Academic Article GET IT
Times cited: 88
Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes, chromosomes & cancer. 2011 Academic Article GET IT
Times cited: 279
Benign mesenchymal stromal cells in human sarcomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 17
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. 2010 GET IT
Times cited: 71
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England journal of medicine. 2010 Academic Article GET IT
Times cited: 4032
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. 2010 GET IT
Times cited: 720
Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Review GET IT
Times cited: 187
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 2010 Academic Article GET IT
Times cited: 268
Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Annals of surgical oncology. 2010 Academic Article GET IT
Times cited: 84
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 147
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature genetics. 2010 Academic Article GET IT
Times cited: 615
IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. The Journal of pathology. 2010 Academic Article GET IT
Times cited: 80
Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 2010 Academic Article GET IT
Times cited: 167
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. Journal of the National Comprehensive Cancer Network : JNCCN. 2010 Conference Paper GET IT
Times cited: 865
Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Archives of pathology & laboratory medicine. 2010 Academic Article GET IT
Times cited: 52
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. 2010 GET IT
Times cited: 314
Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 75
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. The Lancet. Oncology. 2009 Academic Article GET IT
Times cited: 428
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 114
KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer research. 2009 Academic Article GET IT
Times cited: 243
Introduction: the 2008 European society for medical oncology international symposium on sarcomas and gastrointestinal stromal tumors. Seminars in oncology. 2009 Article GET IT
Other targetable sarcomas. Seminars in oncology. 2009 Review GET IT
Times cited: 10
Sarcomas with spindle cell morphology. Seminars in oncology. 2009 Review GET IT
Times cited: 25
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 276
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 190
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 492
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer investigation. 2009 Academic Article GET IT
Times cited: 1
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2009 Academic Article GET IT
Times cited: 1157
A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 159
Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer. 2008 Academic Article GET IT
Times cited: 124
EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases. 2008 GET IT
Times cited: 42
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 666
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes, chromosomes & cancer. 2008 Academic Article GET IT
Times cited: 320
Why do patients with low-grade soft tissue sarcoma die?. Annals of surgical oncology. 2008 Academic Article GET IT
Times cited: 58
Molecular characterization of pediatric gastrointestinal stromal tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 225
DNA copy number analysis in gastrointestinal stromal tumors using gene expression microarrays. Cancer informatics. 2008 Academic Article GET IT
Times cited: 4
Pediatric sarcomas occurring in adults. Journal of surgical oncology. 2008 Review GET IT
Times cited: 30
A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. The American journal of pathology. 2008 Academic Article GET IT
Times cited: 65
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. Journal of the National Cancer Institute. 2008 Letter GET IT
Times cited: 156
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 907
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008 Academic Article GET IT
Times cited: 371
A context dependent role for Wnt signaling in tumorigenesis and stem cells. Cell cycle (Georgetown, Tex.). 2008 Review GET IT
Times cited: 17
Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. The Journal of clinical investigation. 2007 Academic Article GET IT
Times cited: 163
Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis. Cancer. 2007 Academic Article GET IT
Times cited: 39
Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. Leukemia & lymphoma. 2007 Article GET IT
Times cited: 8
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 120
CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' reply. The Lancet. Oncology. 2007 Letter GET IT
Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. The oncologist. 2007 Review GET IT
Times cited: 85
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer research. 2007 Academic Article GET IT
Times cited: 191
Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Annals of surgery. 2007 Academic Article GET IT
Times cited: 180
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2007 Review GET IT
Times cited: 563
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 515
Opportunities for improving the therapeutic ratio for patients with sarcoma. The Lancet. Oncology. 2007 Review GET IT
Times cited: 138
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature medicine. 2007 Academic Article GET IT
Times cited: 255
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 199
Recent advances in therapy for gastrointestinal stromal tumors. Current oncology reports. 2007 Review GET IT
Times cited: 14
A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Digestive diseases and sciences. 2007 Academic Article GET IT
Times cited: 70
Evidence-based recommendations for local therapy for soft tissue sarcomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Review GET IT
Times cited: 131
Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Annals of surgery. 2007 Academic Article GET IT
Times cited: 279
Gastrointestinal Stromal Tumors (GIST) and Their Management. Gastrointestinal cancer research : GCR. 2007 Academic Article GET IT
Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 98
A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma. 2006 Academic Article GET IT
Times cited: 32
Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Annals of surgical oncology. 2006 Academic Article GET IT
Times cited: 102
The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Letter GET IT
Times cited: 26
Future directions for immunotherapeutic intervention against sarcomas. Current opinion in oncology. 2006 Review GET IT
Times cited: 22
Altered bone and mineral metabolism in patients receiving imatinib mesylate. The New England journal of medicine. 2006 Academic Article GET IT
Times cited: 232
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 233
Metastatic colon cancer to the ovaries in a Krukenberg-like pattern. 2005 GET IT
Times cited: 1
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 645
Mechanisms of sarcomagenesis. Hematology/oncology clinics of North America. 2005 Review GET IT
Times cited: 20
A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer journal (Sudbury, Mass.). 2005 Academic Article GET IT
Times cited: 281
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005 Academic Article GET IT
Times cited: 74
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 105
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 153
Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 179
NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2004 Academic Article GET IT
Times cited: 169
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 280
Role of chemotherapy in patients with soft tissue sarcomas. Expert review of anticancer therapy. 2004 Review GET IT
Times cited: 21
Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 100
Gastrointestinal Stromal Tumors Respond to Tyrosine Kinase-targeted Therapy. Current treatment options in gastroenterology. 2004 Academic Article GET IT
Times cited: 23
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 312
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer. 2003 Academic Article GET IT
Times cited: 81
Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. The American journal of pathology. 2003 Academic Article GET IT
Times cited: 199
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proceedings of the National Academy of Sciences of the United States of America. 2003 Academic Article GET IT
Times cited: 188
Immunity against soft-tissue sarcomas. Current oncology reports. 2003 Review GET IT
Times cited: 8
Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Current problems in surgery. 2003 Information Resource GET IT
Times cited: 23
Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. 2002 GET IT
Times cited: 223
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer chemotherapy and pharmacology. 2002 Academic Article GET IT
Times cited: 62
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 546
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. The oncologist. 2002 Academic Article GET IT
Times cited: 50
Multidisciplinary management of soft-tissue sarcomas. Cancer investigation. 2002 Review GET IT
Times cited: 3
Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Current opinion in oncology. 2001 Review GET IT
Times cited: 25
Cascades of transcriptional induction during human lymphocyte activation. European journal of cell biology. 2001 Academic Article GET IT
Times cited: 32
Sarcoma. The oncologist. 2001 Review GET IT
Times cited: 7
Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. International journal of cancer. 1996 Academic Article GET IT
Times cited: 159
Mapping of the genes for human endoplasmic reticular heat shock protein gp96/grp94. Somatic cell and molecular genetics. 1993 Academic Article GET IT
Times cited: 23
Stress-induced proteins in immune response to cancer. Current topics in microbiology and immunology. 1991 Review GET IT
Times cited: 178
Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteins. Proceedings of the National Academy of Sciences of the United States of America. 1990 Academic Article GET IT
Times cited: 127
Divalent cations regulate glucagon binding. Evidence for actions on receptor-Ns complexes and on receptors uncoupled from Ns. Biochemistry. 1988 Academic Article GET IT
Times cited: 9

more ...

less ...

Background

education and training

Ph.D., Cornell University Graduate School of Medical Sciences 91
M.D., Cornell University Medical College 1992
B.A., Northwestern University 1985

Contact

full name

Robert Maki

VIVO Weill Cornell Medical College

Robert Maki Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name